EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.

Gang XiaoLi-Lian JinChao-Qun LiuYong-Chun WangYa-Ming MengZhong-Guo ZhouJing ChenXing-Juan YuYao-Jun ZhangJing XuLimin Zheng

Published in: Journal for immunotherapy of cancer (2019)

The epigenetic modificator EZH2 can suppress the expression of immune checkpoint inhibitor PD-L1 by directly upregulating the promoter H3K27me3 levels of CD274 and IRF1 in hepatoma cells, and might serve as a potential therapeutic target for combination of immunotherapy for immune-activated HCC.

Keyphrases

dna methylation
induced apoptosis
poor prognosis
long non coding rna
gene expression
long noncoding rna
cell cycle arrest
transcription factor
dendritic cells
endoplasmic reticulum stress
human health
cell death
immune response
risk assessment
nk cells